| Biomarker ID | 1822 |
| PMID | 30616540 |
| Year | 2019 |
| Biomarker | BUB1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Methylated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 1.31 (95% CI: 0.908-1.889) |
| Effect on Pathways | Pathways include: Aurora B signaling, Mitotic prometaphase, Polo-like kinase 1 (PLK1) pathway, p73 transcription factor network, Progesterone-mediated oocyte maturation |
| Experiment | Biochemical Recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 158 patients from TCGA were taken into account for this study who had Gleason Score 7. 13 patients experienced Biochemical Recurrence |
| Senstivity | 92% |
| Specificity | 58% |
| AUC | 0.72 |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | RNA-Seq |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |